OTC vaginal contraceptives TFM vacated; FDA asks for NDAs/ANDAs.
This article was originally published in The Tan Sheet
Executive Summary
OTC VAGINAL CONTRACEPTIVE CLINICAL TRIALS UNDER "ACTUAL USE" CONDITIONS are required under FDA's tentative final monograph covering over-the-counter vaginal contraceptives. Published in the Feb. 3 Federal Register, the TFM would require manufacturers of OTC vaginal contraceptives to obtain approved NDAs or ANDAs for their products and test each product "in appropriate clinical trials under actual conditions of use."
You may also be interested in...
Vaginal Contraceptive N-9 Label Warnings Urged “As Soon As Possible” – FDA
Manufacturers of vaginal contraceptives containing nonoxynol-9 should voluntarily implement proposed label warnings about increased vaginal irritation and HIV infection risk "as soon as possible," FDA advises in a 1Jan. 16 proposed rule
Vaginal Contraceptive N-9 Label Warnings Urged “As Soon As Possible” – FDA
Manufacturers of vaginal contraceptives containing nonoxynol-9 should voluntarily implement proposed label warnings about increased vaginal irritation and HIV infection risk "as soon as possible," FDA advises in a 1Jan. 16 proposed rule
Vaginal Contraceptive N-9 Label Warnings Urged “As Soon As Possible” – FDA
Manufacturers of vaginal contraceptives containing nonoxynol-9 should voluntarily implement proposed label warnings about increased vaginal irritation and HIV infection risk "as soon as possible," FDA advises in a 1Jan. 16 proposed rule